Par Pharmaceutical Companies, Inc. (PRX) received a brokerage firm upgrade today, which is helping it to gain during a rather muted morning session.

< ?DART(15);?> In addition, PRX has been enjoying rising earnings estimates that have pushed the 2009 and 2010 Zacks Consensus Estimates higher in just the past 7 days.

The company made the Zacks #1 Rank Top Performers List for Thursday with shares that are up approximately 4.4%. Volume is at 716,000 shares; above the daily average of 301,000.

Par Pharmaceutical develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets.

It is part of the Medical-Generic Drugs industry. There are 3 other names from this space on today's Zacks #1 Rank List: Dr. Reddy's Laboratories Ltd. (RDY), Hi-Tech Pharmacal Company, Inc. (HITK) and Impax Laboratories, Inc. (IPXL).

Earnings Estimates

For this year,

...

Novartis (NVS) is expected to launch its high blood pressure drug Valturna shortly after the recent US Food and Drug Administration approval. The drug is a single-pill combination of Diovan (valsartan), an angiotensin receptor blocker and Tekturna (aliskiren), the only approved direct renin inhibitor. We believe the approval is quite significant as Diovan, one of Novartis’ top-selling drugs with global sales of $5.7 billion in 2008, is losing patent protection in most European Union countries in 2011 and in the U.S. in 2012. Competition is likely to intensify shortly as Merck’s (MRK) Cozaar (2008 sales of $3.5 billion) will lose exclusivity in the U.S. in 2010, bringing in low-priced generics. The approval was based on a randomized, double-blind, placebo-controlled clinical trial on 1800 patients. The trial studied the impact of valsartan (160 mg and 320 mg) and aliskiren (150 mg and 300 mg) independently as ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

 

Friday September 18, 2009

DrStockPick.com Stock Report!

PWRM, IBM, NWMT, CVAT, CSRH, F, AQNM, NVS

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Friday September 18, 2009

DrStockPick.com Stock Report!

PWRM, Power 3 Medical Products Inc, PWRM.OB

NVS, Novartis AG

**************************************************************

Power3 Medical Products, Inc. Headlines Session at International Molecular Diagnostic Meeting in China

- Power3 Medical Products, Inc. a Leader in Neurodegenerative Disease and Cancer Diagnostic Biomarkers Announces its Chief Scientific Officer is Chair and Keynote Speaker of Session at the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 2009 -

Power3 Medical Products, Inc. (OTC BB: PWRM), is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development

...

The US Food and Drug Administration recently approved Novartis’ (NVS) Valturna for high blood pressure. The drug is a single-pill combination of Diovan (valsartan), an angiotensin receptor blocker, and Tekturna (aliskiren), the only approved direct renin inhibitor.

We believe the approval is quite significant as Diovan, one of Novartis’ top-selling drugs with global sales of $5.7 billion in 2008 is losing patent protection in most European Union countries in 2011 and in the U.S. in 2012. Competition is likely to intensify shortly as Merck’s (MRK) Cozaar (2008 sales of $3.5 billion) will lose exclusivity in the U.S. in 2010, bringing in low-priced generics.

The approval was based on a randomized, double-blind, placebo-controlled clinical trial on 1800 patients. The trial studied the impact of valsartan (160 mg and 320 mg) and aliskiren (150 mg and 300 mg) independently as well as in a combination therapy. It was found

...

The Massachusetts Company Cellceutix announced a major acquisition today of a new compound with high blood pressure lowering properties. The emerging, young bio-pharmaceutical company, which is in the business of developing small-molecule therapies in the areas of unmet medical needs, has acquired the right to the compound KM 732.

Preliminary testing revealed that test animals showed a significant decrease in both systolic and diastolic blood pressure compared to controls, with no apparent toxicity. Clinical observation of the animals indicated that blood pressure was reduced within a few minutes of the administration of the compound. The company plans to conduct proof of concept studies in large animals to evaluate the compound’s potential for development to treat hypertensive emergency. Hypertensive emergency is a potentially life-threatening condition characterized by uncontrolled blood pressure leading to damage to other organs.

When asked about the effect this new compound will have on Cellceutix, George

...

Large Market Opportunity...

In our view, obesity remains the single largest opportunity for a new pharmaceutical product today. Roughly two-thirds of the U.S. population is overweight. The number is expected to grow to 75% by 2015. There is massive unmet medical need and clear pharmacoeconomic benefits to curtailing the problem.

According to the Journal of Health Affairs, obesity costs Americans $147 billion per year in total medical costs. This is 10% of all healthcare spending, and that number has doubled since 1998. It is likely to continue to surge in the years to come. Obesity is associated with an enormous number of co-morbidities, including high cholesterol, high blood pressure, heart disease, diabetes, joint and muscle pain, as well as depression and fibromyalgia. Studies have shown that reducing body weight by as little as 5% has a meaningful impact on reducing these co-morbidities.

New Products Are Coming...

Several biotechnology companies are working on the

...

With stocks having been beaten down so badly these past few quarters, investors are getting tired of losing money. However, for those of us who are not about to retire, we have to allow some room for patience in our investing strategies. Investing in a company whose stock price appreciates year-over-year is optimal, but if you’ve got some time to spare, invest in companies that you know will be more valuable 10 to 15 years down the road. With heart disease persisting as the number one killer worldwide, you should be looking to prop up your portfolio over the long run with stocks dedicated to fighting heart disease . Combined with the aging world population, these two stocks are poised to capitalize on the declining health of the eldest generation:

Medtronic Inc.

Medtronic Inc. [MDT:

...